002907 华森制药
已收盘 02-26 15:00:00
资讯
新帖
简况
华森制药(002907.SZ)：HSN002066C1片药物临床试验获批准
智通财经 · 02-24 17:33
华森制药(002907.SZ)：HSN002066C1片药物临床试验获批准
2月6日华森制药发布公告，股东减持88.87万股
证券之星 · 02-06
2月6日华森制药发布公告，股东减持88.87万股
华森制药（002907）披露克唑替尼胶囊完成境内生产药品备案，1月30日股价下跌0.34%
证券之星 · 01-30
华森制药（002907）披露克唑替尼胶囊完成境内生产药品备案，1月30日股价下跌0.34%
华森制药最新公告：收到8个药品的药品再注册批准通知书
证券之星 · 01-14
华森制药最新公告：收到8个药品的药品再注册批准通知书
1月13日华森制药现2笔折价12%的大宗交易 合计成交1680.96万元
证券之星 · 01-13
1月13日华森制药现2笔折价12%的大宗交易 合计成交1680.96万元
华森制药：1月8日高管游洪涛减持股份合计15.28万股
证券之星 · 01-09
华森制药：1月8日高管游洪涛减持股份合计15.28万股
华森制药：1月7日高管游洪涛减持股份合计16.5万股
证券之星 · 01-08
华森制药：1月7日高管游洪涛减持股份合计16.5万股
1月7日华森制药现1笔折价10.47%的大宗交易 合计成交225.72万元
证券之星 · 01-07
1月7日华森制药现1笔折价10.47%的大宗交易 合计成交225.72万元
1月6日华森制药现1笔折价10.13%的大宗交易 合计成交200.12万元
证券之星 · 01-06
1月6日华森制药现1笔折价10.13%的大宗交易 合计成交200.12万元
每周股票复盘：华森制药（002907）特医食品生产许可获批
证券之星 · 01-03
每周股票复盘：华森制药（002907）特医食品生产许可获批
华森制药（002907）披露公司特殊医学用途配方食品生产许可证变更，12月30日股价下跌0.53%
证券之星 · 2025-12-30
华森制药（002907）披露公司特殊医学用途配方食品生产许可证变更，12月30日股价下跌0.53%
华森制药（002907）披露公司药品生产许可证变更公告，12月26日股价下跌2.18%
证券之星 · 2025-12-26
华森制药（002907）披露公司药品生产许可证变更公告，12月26日股价下跌2.18%
华森制药最新公告：收到注射用奥美拉唑钠药品再注册批准通知书
证券之星 · 2025-12-23
华森制药最新公告：收到注射用奥美拉唑钠药品再注册批准通知书
华森制药：12月19日高管游洪涛减持股份合计29.54万股
证券之星 · 2025-12-22
华森制药：12月19日高管游洪涛减持股份合计29.54万股
12月19日华森制药现2笔折价10.78%的大宗交易 合计成交400.86万元
证券之星 · 2025-12-19
12月19日华森制药现2笔折价10.78%的大宗交易 合计成交400.86万元
华森制药：12月12日高管游洪涛减持股份合计14.5万股
证券之星 · 2025-12-15
华森制药：12月12日高管游洪涛减持股份合计14.5万股
12月4日华森制药发布公告，股东减持51.4万股
证券之星 · 2025-12-04
12月4日华森制药发布公告，股东减持51.4万股
华森制药：12月1日高管游洪涛减持股份合计13.8万股
证券之星 · 2025-12-02
华森制药：12月1日高管游洪涛减持股份合计13.8万股
12月1日华森制药现1笔折价10.5%的大宗交易 合计成交201.2万元
证券之星 · 2025-12-01
12月1日华森制药现1笔折价10.5%的大宗交易 合计成交201.2万元
华森制药：11月26日高管游洪涛减持股份合计13.6万股
证券之星 · 2025-11-27
华森制药：11月26日高管游洪涛减持股份合计13.6万股
暂无数据
公司概况
公司名称：
重庆华森制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-10-20
主营业务：
重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是耳鼻喉科用药、消化系统用药、精神神经系统用药、其他领域用药、医药商业、医药零售、其他业务。
发行价格：
4.53
{"stockData":{"symbol":"002907","market":"SZ","secType":"STK","nameCN":"华森制药","latestPrice":14.94,"timestamp":1772089398000,"preClose":14.82,"halted":0,"volume":2506980,"delay":0,"changeRate":0.0081,"floatShares":300000000,"shares":418000000,"eps":0.1787,"marketStatus":"已收盘","change":0.12,"latestTime":"02-26 15:00:00","open":14.77,"high":14.94,"low":14.76,"amount":37261600,"amplitude":0.0121,"askPrice":14.94,"askSize":338,"bidPrice":14.93,"bidSize":352,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772155800000},"marketStatusCode":5,"adr":0,"adjPreClose":14.82,"symbolType":"stock","openAndCloseTimeList":[[1772069400000,1772076600000],[1772082000000,1772089200000]],"highLimit":16.3,"lowLimit":13.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417596314,"isCdr":false,"pbRate":3.66,"roa":"--","peRate":83.603805,"roe":"4.31%","epsLYR":0.1837,"committee":-0.261403,"marketValue":6239000000,"turnoverRate":0.0084,"status":0,"floatMarketCap":4481000000},"requestUrl":"/m/hq/s/002907/tweets","defaultTab":"tweets","newsList":[{"id":"2613915947","title":"华森制药(002907.SZ)：HSN002066C1片药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613915947","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613915947?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:33","pubTimestamp":1771925592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华森制药(002907.SZ)公告，公司子公司重庆华森英诺生物科技有限公司(简称“华森英诺”)于近日收到国家药品监督管理局核准签发的HSN002066C1片两个规格的《药物临床试验批准通知书》。公告显示，HSN002066C1片(其游离碱为HSN002B015)是由华森英诺自主研发且完全享有自主知识产权的一种选择性聚二磷酸腺苷-核糖聚合酶7(PARP7)小分子抑制剂，临床拟口服用于晚期恶性实体瘤患者的治疗。HSN002066C1是一种强效和高选择性的PARP7抑制剂，口服给药在小鼠中暴露量较高，单药或联合用药导致不同肿瘤模型中具有较为显著的肿瘤抑制活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华森制药(002907.SZ)：HSN002066C1片药物临床试验获批准","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2609952585","title":"2月6日华森制药发布公告，股东减持88.87万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609952585","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609952585?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:01","pubTimestamp":1770382875,"startTime":"0","endTime":"0","summary":"证券之星消息，2月6日华森制药发布公告《华森制药:关于公司控股股东一致行动人减持时间届满暨减持结果公告》，其股东上海添橙投资管理有限公司-添橙添利一号私募证券投资基金于2025年12月23日至2026年1月26日间合计减持88.87万股，占公司目前总股本的0.2128%，变动期间该股股价上涨2.77%，截止1月26日收盘报15.57元。股东增减持详情见下表：根据华森制药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600039027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2607939042","title":"华森制药（002907）披露克唑替尼胶囊完成境内生产药品备案，1月30日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607939042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607939042?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:19","pubTimestamp":1769786351,"startTime":"0","endTime":"0","summary":"近日，重庆华森制药股份有限公司发布《关于公司产品完成境内生产药品备案的公告》。公告显示，公司克唑替尼胶囊完成境内生产药品备案，有效期由18个月延长至24个月，并在说明书和标签中增加“通过一致性评价”标识。备案号为渝备2025059388，药品批准文号为国药准字H20255702，上市许可持有人和生产企业均为重庆华森制药股份有限公司，备案机关为重庆市药品监督管理局，备案日期为2026年1月4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2603699904","title":"华森制药最新公告：收到8个药品的药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699904","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603699904?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:23","pubTimestamp":1768382616,"startTime":"0","endTime":"0","summary":"华森制药(002907.SZ)公告称，公司近日收到重庆市药品监督管理局核准签发的关于公司8个药品的《药品再注册批准通知书》。这些药品包括注射用甲磺酸培氟沙星（0.2g和0.4g）、注射用胞磷胆碱钠、注射用阿昔洛韦、西洛他唑胶囊、注射用布美他尼、注射用亚叶酸钙（25mg和100mg）。这些药品的再注册批准将确保其正常生产和销售，但短期内不会对公司经营业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400029068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2603502307","title":"1月13日华森制药现2笔折价12%的大宗交易 合计成交1680.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603502307","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603502307?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:33","pubTimestamp":1768296809,"startTime":"0","endTime":"0","summary":"证券之星消息，1月13日华森制药发生大宗交易，交易数据如下：近三个月该股共发生21笔大宗交易，合计成交5.97万手，折价成交21笔。该股近期无解禁股上市。截至2026年1月13日收盘，华森制药(002907)报收于15.91元，上涨3.38%，换手率3.99%，成交量11.97万手，成交额1.9亿元。该股近半年内有股东持股变动，合计净减持653.53万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300029396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2602796963","title":"华森制药：1月8日高管游洪涛减持股份合计15.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602796963","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602796963?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:36","pubTimestamp":1767965768,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月9日市场公开信息、上市公司公告及交易所披露数据整理，华森制药（002907）最新董监高及相关人员股份变动情况：2026年1月8日公司董事,高管游洪涛共减持公司股份15.28万股，占公司总股本为0.0366%。变动期间公司股价上涨0.26%，1月8日当日收盘报15.32元。华森制药近半年内的董监高及核心技术人员增减持详情如下：华森制药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900039637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2601836498","title":"华森制药：1月7日高管游洪涛减持股份合计16.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601836498","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601836498?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:02","pubTimestamp":1767877340,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月8日市场公开信息、上市公司公告及交易所披露数据整理，华森制药（002907）最新董监高及相关人员股份变动情况：2026年1月7日公司董事,高管游洪涛共减持公司股份16.5万股，占公司总股本为0.0395%。变动期间公司股价上涨0.53%，1月7日当日收盘报15.28元。华森制药近半年内的董监高及核心技术人员增减持详情如下：华森制药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800037364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2601876105","title":"1月7日华森制药现1笔折价10.47%的大宗交易 合计成交225.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601876105","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601876105?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:32","pubTimestamp":1767778333,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日华森制药发生大宗交易，交易数据如下：大宗交易成交价格13.68元，相对当日收盘价折价10.47%，成交16.5万股，成交金额225.72万元，买方营业部为机构专用，卖方营业部为华泰证券股份有限公司宜都长江大道证券营业部。近三个月该股共发生18笔大宗交易，合计成交4.61万手，折价成交18笔。截至2026年1月7日收盘，华森制药报收于15.28元，上涨0.53%，换手率1.0%，成交量3.0万手，成交额4570.37万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700026944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2601089842","title":"1月6日华森制药现1笔折价10.13%的大宗交易 合计成交200.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601089842","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601089842?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:31","pubTimestamp":1767691910,"startTime":"0","endTime":"0","summary":"证券之星消息，1月6日华森制药发生大宗交易，交易数据如下：大宗交易成交价格13.66元，相对当日收盘价折价10.13%，成交14.65万股，成交金额200.12万元，买方营业部为机构专用，卖方营业部为华泰证券股份有限公司宜都长江大道证券营业部。近三个月该股共发生17笔大宗交易，合计成交4.45万手，折价成交17笔。该股近期无解禁股上市。截至2026年1月6日收盘，华森制药报收于15.2元，上涨0.13%，换手率1.03%，成交量3.08万手，成交额4670.66万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600029095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2600067225","title":"每周股票复盘：华森制药（002907）特医食品生产许可获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067225","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067225?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:00","pubTimestamp":1767380434,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，华森制药报收于14.81元，较上周的15.23元下跌2.76%。本周，华森制药12月29日盘中最高价报15.2元。华森制药当前最新总市值61.85亿元，在中药板块市值排名35/67，在两市A股市值排名2856/5181。本周关注点公司公告汇总：华森制药获特殊医学用途配方食品生产许可证，新增食品类别范围。公司已于2025年11月取得国家市场监督管理总局签发的特医食品注册证书。本次变更短期内对公司业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2595071875","title":"华森制药（002907）披露公司特殊医学用途配方食品生产许可证变更，12月30日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595071875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595071875?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:32","pubTimestamp":1767105140,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，华森制药报收于14.96元，较前一交易日下跌0.53%，最新总市值为62.47亿元。公司近日发布公告称，重庆华森制药股份有限公司近日收到重庆市市场监督管理局核发的《特殊医学用途配方食品生产许可证》，许可证编号SC12850000050231，变更内容为新增食品类别范围，包括特殊医学用途配方食品和饮料。公司已于2025年11月取得国家市场监督管理总局签发的特医食品注册证书。本次变更短期内对公司业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2594947752","title":"华森制药（002907）披露公司药品生产许可证变更公告，12月26日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594947752","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594947752?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:55","pubTimestamp":1766760913,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，华森制药报收于15.23元，较前一交易日下跌2.18%，最新总市值为63.6亿元。该股当日开盘15.45元，最高15.45元，最低15.12元，成交额达6714.44万元，换手率为1.47%。本次变更有助于提高公司产能利用率，短期内对公司业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2593496845","title":"华森制药最新公告：收到注射用奥美拉唑钠药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593496845","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593496845?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:43","pubTimestamp":1766483030,"startTime":"0","endTime":"0","summary":"华森制药(002907.SZ)公告称，公司近日收到重庆市药品监督管理局核准签发的关于公司产品注射用奥美拉唑钠的《药品再注册批准通知书》。该产品为上消化道出血经典用药，临床必需，为国家医保目录产品，获多项指南共识推荐。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300028286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2593480388","title":"华森制药：12月19日高管游洪涛减持股份合计29.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480388","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593480388?lang=zh_cn&edition=full","pubTime":"2025-12-22 21:02","pubTimestamp":1766408541,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月22日市场公开信息、上市公司公告及交易所披露数据整理，华森制药（002907）最新董监高及相关人员股份变动情况：2025年12月19日公司董事,高管游洪涛共减持公司股份29.54万股，占公司总股本为0.0707%。变动期间公司股价上涨0.86%，12月19日当日收盘报15.21元。华森制药近半年内的董监高及核心技术人员增减持详情如下：华森制药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200031931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2592157150","title":"12月19日华森制药现2笔折价10.78%的大宗交易 合计成交400.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592157150","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592157150?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:41","pubTimestamp":1766137305,"startTime":"0","endTime":"0","summary":"证券之星消息，12月19日华森制药发生大宗交易，交易数据如下：近三个月该股共发生16笔大宗交易，合计成交4.3万手，折价成交16笔。该股近期无解禁股上市。截至2025年12月19日收盘，华森制药(002907)报收于15.21元，上涨0.86%，换手率0.47%，成交量1.41万手，成交额2133.74万元。该股近半年内有股东持股变动，合计净减持969.35万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900026924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2591649168","title":"华森制药：12月12日高管游洪涛减持股份合计14.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649168","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591649168?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:02","pubTimestamp":1765803741,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月15日市场公开信息、上市公司公告及交易所披露数据整理，华森制药（002907）最新董监高及相关人员股份变动情况：2025年12月12日公司董事,高管游洪涛共减持公司股份14.5万股，占公司总股本为0.0347%。变动期间公司股价上涨0.91%，12月12日当日收盘报15.52元。华森制药近半年内的董监高及核心技术人员增减持详情如下：华森制药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500032681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2588885979","title":"12月4日华森制药发布公告，股东减持51.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588885979","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588885979?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:01","pubTimestamp":1764846091,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日华森制药发布公告《华森制药:关于控股股东及其一致行动人持股变动触及1%整数倍的公告》，其股东上海添橙投资管理有限公司-添橙添利一号私募证券投资基金于2025年11月7日至2025年12月3日间合计减持51.4万股，占公司目前总股本的0.1231%，变动期间该股股价下跌1.29%，截止12月3日收盘报16.08元。股东增减持详情见下表：根据华森制药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400032300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2588537270","title":"华森制药：12月1日高管游洪涛减持股份合计13.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588537270","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588537270?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:02","pubTimestamp":1764680566,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月2日市场公开信息、上市公司公告及交易所披露数据整理，华森制药（002907）最新董监高及相关人员股份变动情况：2025年12月1日公司董事,高管游洪涛共减持公司股份13.8万股，占公司总股本为0.033%。变动期间公司股价上涨0.56%，12月1日当日收盘报16.29元。华森制药近半年内的董监高及核心技术人员增减持详情如下：华森制药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200037317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2588723008","title":"12月1日华森制药现1笔折价10.5%的大宗交易 合计成交201.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588723008","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588723008?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:42","pubTimestamp":1764582143,"startTime":"0","endTime":"0","summary":"证券之星消息，12月1日华森制药发生大宗交易，交易数据如下：大宗交易成交价格14.58元，相对当日收盘价折价10.5%，成交13.8万股，成交金额201.2万元，买方营业部为机构专用，卖方营业部为华泰证券股份有限公司宜都长江大道证券营业部。近三个月该股共发生9笔大宗交易，合计成交1.82万手，折价成交9笔。截至2025年12月1日收盘，华森制药报收于16.29元，上涨0.56%，换手率0.57%，成交量1.71万手，成交额2792.05万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2586228348","title":"华森制药：11月26日高管游洪涛减持股份合计13.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586228348","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586228348?lang=zh_cn&edition=full","pubTime":"2025-11-27 21:01","pubTimestamp":1764248505,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月27日市场公开信息、上市公司公告及交易所披露数据整理，华森制药（002907）最新董监高及相关人员股份变动情况：2025年11月26日公司董事,高管游洪涛共减持公司股份13.6万股，占公司总股本为0.0326%。变动期间公司股价下跌0.37%，11月26日当日收盘报16.31元。华森制药近半年内的董监高及核心技术人员增减持详情如下：华森制药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700035974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772115722778,"stockEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":-0.0482},{"period":"3month","weight":-0.0947},{"period":"6month","weight":-0.1402},{"period":"1year","weight":0.1827},{"period":"ytd","weight":0.0007}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0702},{"period":"6month","weight":0.075},{"period":"1year","weight":0.2394},{"period":"ytd","weight":0.0449}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆华森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33091人(较上一季度增加0.84%)","perCapita":"9063股","listingDate":"2017-10-20","address":"重庆市荣昌区工业园区","registeredCapital":"41759万元","survey":" 重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是耳鼻喉科用药、消化系统用药、精神神经系统用药、其他领域用药、医药商业、医药零售、其他业务。","listedPrice":4.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华森制药,002907,华森制药股票,华森制药股票老虎,华森制药股票老虎国际,华森制药行情,华森制药股票行情,华森制药股价,华森制药股市,华森制药股票价格,华森制药股票交易,华森制药股票购买,华森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}